Regramostim

Identification

Generic Name
Regramostim
DrugBank Accession Number
DB05386
Background

Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. GM-CSF stimulates proliferation, activation and differentiation of macrophages and granulocytes and their progenitors.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Colony-stimulating factor 2 (human clone pCSF-1 protein moiety reduced), glycoform GMC 89-107
  • GM-CSF (CHO cell)
  • Regramostim
  • Regramostime
  • Regramostimum
  • rhGm-CSF
External IDs
  • GMC 89-107

Pharmacology

Indication

Investigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

This drug activates mononuclear phagocytes, promotes migration of epithelial cells, and further regulates cytokine production. In 2 recent placebo-controlled studies involving venous leg ulceration, subcutaneous perilesional injections of recombinant human granulocyte-macrophage colony-stimulating factor were found to be significantly better than placebo in the time to complete wound healing. In other studies, recombinant human granulocyte-macrophage colony-stimulating factor was administered topically to wounds. Several case reports have also demonstrated the use of recombinant human granulocyte-macrophage colony-stimulating factor for postsurgical wounds, chronic leg ulcers of sickle cell anemia patients, and refract and refractory pyoderma gangrenosum.

TargetActionsOrganism
UGranulocyte-macrophage colony-stimulating factor receptor subunit alphaNot AvailableHumans
UGM-CSF receptor alpha subunitNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololRegramostim may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Regramostim is combined with Acetylcholine.
AclidiniumRegramostim may increase the neuromuscular blocking activities of Aclidinium.
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Regramostim.
AmifampridineThe risk or severity of adverse effects can be increased when Regramostim is combined with Amifampridine.
AmitriptylineThe therapeutic efficacy of Amitriptyline can be decreased when used in combination with Regramostim.
AmobarbitalThe therapeutic efficacy of Amobarbital can be decreased when used in combination with Regramostim.
AmoxapineThe therapeutic efficacy of Amoxapine can be decreased when used in combination with Regramostim.
Anisotropine methylbromideThe therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Regramostim.
AripiprazoleThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Regramostim.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
KR89Q40F01
CAS number
127757-91-9

References

General References
  1. Sardana R, Dudani AK, Tackaberry E, Alli Z, Porter S, Rowlandson K, Ganz P, Altosaar I: Biologically active human GM-CSF produced in the seeds of transgenic rice plants. Transgenic Res. 2007 Dec;16(6):713-21. Epub 2007 Feb 16. [Article]
  2. Rosas M, Gordon S, Taylor PR: Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice. Eur J Immunol. 2007 Sep;37(9):2518-28. [Article]
PubChem Substance
347910111

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionMycoses1
4CompletedTreatmentDeep Partial Thickness Burn1
2CompletedTreatmentPerforated Appendicitis1
2CompletedTreatmentProstate Cancer3
2Not Yet RecruitingTreatmentThymic Epithelial Tumors1
2RecruitingTreatmentRespiratory Distress Syndrome, Acute (ARDS)1
2RecruitingTreatmentVenous Leg Ulcer (VLU)1
2TerminatedTreatmentCystic Fibrosis (CF) / Mycobacterium Infections, Nontuberculous1
2Unknown StatusTreatmentMalignant Neoplasm of Colon1
2Unknown StatusTreatmentMalignant Neoplasm of Nasopharynx1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells.
Gene Name
CSF2RA
Uniprot ID
P15509
Uniprot Name
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha
Molecular Weight
46206.185 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
CSF2RA
Uniprot ID
Q16498
Uniprot Name
GM-CSF receptor alpha subunit
Molecular Weight
3014.39 Da

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Takahashi M, Nikkuni K, Moriyama Y, Shibata A: GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol. Am J Hematol. 1991 Mar;36(3):213-4. [Article]

Drug created on November 18, 2007 18:24 / Updated on February 21, 2021 18:51